New gout drug aims to crush flare pain in 72 hours
NCT ID NCT07453004
First seen Mar 12, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study tests a new medicine, punarlimab, for people with acute gouty arthritis (sudden, painful joint flares). About 170 adults who have had at least 3 gout attacks in the past year will receive either punarlimab or an active comparator. The main goal is to see how well punarlimab reduces pain 72 hours after the first dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GOUTY ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.